Alpha/beta (a/b) ratio for prostate cancer derived from external beam radiotherapy and brachytherapy boost

British Journal of Radiology

Volumn 89, Issue 1061, 2016, Pages

  Boonstra, Philip S ^a   Taylor, Jeremy M G ^a   Smolska Ciszewska, Beata ^b   Behrendt, Katarzyna ^b   Dworzecki, Tomasz ^b   Gawkowska Suwinska, Marzena ^b   Bialas, Brygida ^b   Suwinski, Rafal ^b  

^a UNIVERSITY OF MICHIGAN   (United States)

^b INSTITUTE OF ONCOLOGY   (Poland)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIANDROGEN; ANTINEOPLASTIC AGENT; PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ALPHA BETA RATIO; ANDROGEN DEPRIVATION THERAPY; ARTICLE; BIOCHEMICAL RECURRENCE FREE SURVIVAL; BRACHYTHERAPY; CANCER CELL; CANCER PATIENT; COMPUTER ASSISTED TOMOGRAPHY; CONFORMAL RADIOTHERAPY; CONTROLLED STUDY; EXTERNAL BEAM RADIOTHERAPY; HUMAN; LINEAR ACCELERATOR; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; NEOADJUVANT THERAPY; NUCLEAR MAGNETIC RESONANCE IMAGING; PROSTATE ADENOCARCINOMA; RADIATION DOSE; RADIATION DOSE FRACTIONATION; RADIOLOGICAL PARAMETERS; STATISTICAL MODEL; TREATMENT OUTCOME; VERY ELDERLY; BLOOD; MULTIMODALITY CANCER THERAPY; PROSTATIC NEOPLASMS; RETROSPECTIVE STUDY;

ADULT; AGED; AGED, 80 AND OVER; ANDROGEN ANTAGONISTS; BRACHYTHERAPY; COMBINED MODALITY THERAPY; DOSE FRACTIONATION; HUMANS; MALE; MIDDLE AGED; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RADIOTHERAPY, CONFORMAL; RETROSPECTIVE STUDIES;

EID: 84989835357     PISSN: 00071285     EISSN: None     Source Type: Journal    
DOI: 10.1259/bjr.20150957     Document Type: Article

References (27)

1. Brenner DJ, Hall EJ. Fractionation and protraction for radiotherapy of prostate carcinoma. Int J Radiat Oncol Biol Phys 1999; 43: 1095-101. doi: http://dx.doi.org/10.1016/S0360-3016(98)00438-6
2. Vogelius IR, Bentzen SM. Meta-analysis of the alpha/beta ratio for prostate cancer in the presence of an overall time factor: bad news, good news, or no news? Int J Radiat Oncol Biol Phys 2013; 85: 89-94. doi: http://dx.doi. org/10.1016/j.ijrobp.2012.03.004
3. Wang JZ, Guerrero M, Li XA. How low is the a/b ratio for prostate cancer? Int J Radiat Oncol Biol Phys 2003; 55: 194-203. doi: http://dx.doi. org/10.1016/S0360-3016(02)03828-2
4. Miralbell R, Roberts SA, Zubizarreta E, Hendry JH. Dose-fractionation sensitivity of prostate cancer deduced from radiotherapy outcomes of 5,969 patients in seven international institutional datasets: a/b5 1.4 (0.9-2.2) Gy. Int J Radiat Oncol Biol Phys 2012; 82: e17-24.
5. Proust-Lima C, Taylor JM, Sécher S, Sandler H, Kestin L, Pickles T, et al. Confirmation of a low a/b ratio for prostate cancer treated by external beam radiation therapy alone using a post-treatment repeated-measures model for PSA dynamics. Int J Radiat Oncol Biol Phys 2011; 79: 195-201. doi: http://dx.doi. org/10.1016/j.ijrobp.2009.10.008
6. Williams SG, Taylor JM, Liu N, Tra Y, Duchesne GM, Kestin LL, et al. Use of individual fraction size data from 3756 patients to directly determine the a/b ratio of prostate cancer. Int J Radiat Oncol Biol Phys 2007; 68: 24-33. doi: http://dx.doi. org/10.1016/j.ijrobp.2006.12.036
7. Roberts SA, Miralbell R, Zubizarreta EH, Fowler JF, Hendry JH. A modelled comparison of prostate cancer control rates after high-doserate brachyther-apy (3145 multicentre patients) combined with, or in contrast to, externalbeam radiotherapy. Radiother Oncol 2014; 111: 114-19. doi: http://dx.doi.org/10.1016/j. radonc.2014.01.008
8. Arcangeli G, Saracino B, Gomellini S, Petrongari MG, Arcangeli S, Sentinelli S, et al. A prospective phase III randomized trial of hypofractionation versus conventional fractionation in patients with high-risk prostate cancer. Int J Radiat Oncol Biol Phys 2010; 78: 11-18. doi: http://dx.doi.org/10.1016/j.ijrobp.2009.07.1691
9. Arcangeli S, Strigari L, Gomellini S, Saracino B, Petrongari MG, Pinnaró P, et al. Updated results and patterns of failure in a randomized hypofractionation trial for high-risk prostate cancer. Int J Radiat Oncol Biol Phys 2012; 84: 1172-8. doi: http://dx.doi.org/10.1016/j.ijrobp.2012.02.049
10. Pollack A, Walker G, Horwitz EM, Price R, Feigenberg S, Konski AA, et al. Randomized trial of hypofractionated external-beam radiotherapy for prostate cancer. J Clin Oncol 2013; 31: 3860-8. doi: http://dx.doi.org/10.1200/JCO.2013.51.1972
11. Nahum AE, Movsas B, Horwitz EM, Stobbe CC, Chapman JD. Incorporating clinical measurements of hypoxia into tumor local control modeling of prostate cancer: implications for the a/b ratio. Int J Radiat Oncol Biol Phys 2003; 57: 391-401. doi: http://dx.doi.org/10.1016/S0360-3016(03)00534-0
12. King CR, Mayo CS. Is the prostate a/b ratio of 1.5 from Brenner & Hall a modeling artifact? Int J Radiat Oncol Biol Phys 2000; 47: 536-9. doi: http://dx.doi.org/10.1016/S0360-3016(00)00442-9
13. Afsharpour H, Walsh S, Collins Fekete CA, Vigneault E, Verhaegen F, Beaulieu L. On the sensitivity of a/b prediction to dose calculation methodology in prostate brachytherapy. Int J Radiat Oncol Biol Phys 2014; 88: 345-50. doi: http://dx.doi.org/10.1016/j.ijrobp.2013.11.001
14. Nickers P, Hermesse J, Deneufbourg JM, Vanbelle S, Lartigau E. Which a/b ratio and half-time of repair are useful for predicting outcomes in prostate cancer? Radiother Oncol 2010; 97: 462-6. doi: http://dx.doi.org/10.1016/j.radonc.2010.06.006
15. Shaffer R, Pickles T, Lee R, Moiseenko V. Deriving prostate alpha-beta ratio using carefully matched groups, long follow-up and the phoenix definition of biochemical failure. Int J Radiat Oncol Biol Phys 2011; 79: 1029-36. doi: http://dx.doi.org/10.1016/j.ijrobp.2009.12.058
16. Bentzen SM, Ritter MA. The a/b ratio for prostate cancer: what is it, really? Radiother Oncol 2005; 76: 1-3. doi: http://dx.doi.org/10.1016/j.radonc.2005.06.009
17. Valdagni R, Nahum AE, Magnani T, Italia C, Lanceni A, Montanaro P, et al. Long-term biochemical control of prostate cancer after standard or hyper-fractionation: evidence for different outcomes between low-intermediate and high risk patients. Radiother Oncol 2011; 101: 454-9. doi: http://dx.doi.org/10.1016/j.radonc.2011.07.017
18. Williams SG, Pickles T, Kestin L, Buyyounouski M, Martinez A, Demanes J, et al. Androgen deprivation therapy plus hypofractionated prostate radiotherapy-are we castrating the radiobiological advantage? Int J Radiat Oncol Biol Phys 2008; 72: S73-4. doi: http://dx.doi.org/10.1016/j.ijrobp.2008.06.933
19. Smolska-Ciszewska B, Miszczyk L, Bia?as B, Fija?kowski M, Plewicki G, Gawkowska-Suwińska M, et al. The effectiveness and side effects of conformal external beam radiotherapy combined with high-dose-rate brachytherapy boost compared to conformal external beam radiotherapy alone in patients with prostate cancer. Radiat Oncol 2015; 10: 60. doi: http://dx.doi.org/10.1186/s13014-015-0366-z
20. Roach M 3rd, Hanks G, Thames H Jr, Schellhammer P, Shipley WU, Sokol GH, et al. Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO Phoenix Consensus Conference. Int J Radiat Oncol Biol Phys 2006; 65: 965-74. doi: http://dx.doi. org/10.1016/j.ijrobp.2006.04.029
21. R Core Team. R: a language and environment for statistical computing. Vienna, Austria; 2015. Available from: http://www.R-project.org/
22. Hoskin PJ, Rojas AM, Bownes PJ, Lowe GJ, Ostler PJ, Bryant L. Randomised trial of external beam radiotherapy alone or combined with highdose-rate brachytherapy boost for localised prostate cancer. Radiother Oncol 2012; 103: 217-22. doi: http://dx.doi.org/10.1016/j.radonc.2012.01.007
23. Brenner MJ, Kaplan ID. Is there any benefit from hypofractionation in external-beam irradiation for prostate cancer? J Clin Oncol 2014; 32: 1851-2. doi: http://dx.doi.org/10.1200/JCO.2013.54.4247
24. Vogelius IR, Bentzen SM. Hypofractionated radiation therapy for prostate cancer: more food for thought from recent trial. J Clin Oncol 2014; 32: 1852-1853. doi: http://dx.doi.org/10.1200/JCO.2013.54.8123
25. Pollack A, Walker G, Horwitz EM, Price R, Feigenberg S, Konski AA, et al. Reply to MJ Brenner, et al. and IR Vogelius et al. J Clin Oncol 2014; 32: 1853-1854. doi: http://dx.doi.org/10.1200/JCO.2013.54.7729
26. The START Trialists' Group, Bentzen SM, Agrawal RK, Aird EG, Barrett JM, Barrett-Lee PJ, Bliss JM, et al. The UK Standardisation of Breast Radiotherapy (START) Trial A of radiotherapy hypofractionation for treatment of early breast cancer: a randomised trial. Lancet Oncol 2008; 9: 331-41. doi: http://dx.doi. org/10.1016/S1470-2045(08)70077-9
27. Suwinski R, Wzietek I, Tarnawski R, Namysl-Kaletka A, Kryj M, Chmielarz A, et al. Moderately low alpha/beta ratio for rectal cancer may best explain the outcome of three fractionation schedules of preoperative radiotherapy. Int J Radiat Oncol Biol Phys 2007; 69: 793-9. doi: http://dx.doi.org/10.1016/j. ijrobp.2007.03.046